Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia.

Clinical pharmacology and therapeutics - 1 Feb 2008

Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark R E

Abstract excerpt

Some chronic myeloid leukemia (CML) patients do not respond to imatinib, whereas others lose an initial response. To identify potential imatinib failures, we investigated the expression of imatinib uptake transporter (human organic cation transporter 1; hOCT1) and efflux transporters (ATP-binding...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily G, Member 1
Share to ATP Binding Cassette Transporter, Subfamily G, Member 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzamides

Share to Fusion Proteins, bcr-abl

Share to Imatinib Mesylate

Share to Leukemia, Myeloid

Share to Octamer Transcription Factor-1

Share to Patient Selection

Source

Identifiers

PMID: 17568400
DOI: 10.1038/sj.clpt.6100268

Genes

ABCB1
ABCC1
ABCG2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17568400-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia.PMID 17568400Read ↗

hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia.Semantic proximity Read ↗

hOCT 1 and resistance to imatinibSemantic proximity Read ↗

Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemiaSemantic proximity Read ↗

Genetic variations of hOCT1 gene and CYP3A4/A5 genes and their association with imatinib response in Chronic Myeloid Leukemia.Semantic proximity Read ↗

Factors affecting the response to tyrosine kinase inhibitors in chronic myeloid leukaemiaSemantic proximity Read ↗

Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy.Semantic proximity Read ↗

Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia.Semantic proximity Read ↗

The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia.Semantic proximity Read ↗

The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia.Semantic proximity Read ↗

Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia.Semantic proximity Read ↗

OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients.Semantic proximity Read ↗

The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.